2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5601 Transfusion dependence and disease biology refine transplant decision-making in 636 patients with MDS-h and MDS-LB

Wenjing Guo, PhD, Linlin Liu2, Jia Li3, Erlie Jiang, MD4, Zhijian Xiao5, Sizhou Feng, PhD6
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Introduction: Hypoplastic myelodysplastic neoplasms (MDS-h) and MDS with low blasts (MDS-LB) generally have favorable outcomes, yet the prognostic impact of transfusion dependence (TD) and the survival benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear, particularly in patients who are initially transfusion-independent (TI).

Methods: We retrospectively analyzed 146 patients with MDS-h and 490 with MDS-LB diagnosed according to the World Health Organization (WHO) 2022 criteria at our hospital between June 2016 and June 2024. The prognostic impact of allo-HSCT was evaluated using landmark analyses and time-dependent approaches.

Results: With a median follow-up of 38.9 months (95% CI: 35.7-42.8), 112 patients underwent allo-HSCT. Overall, 69.2% of patients harbored at least one mutation, most frequently U2AF1 (27.3%), ASXL1 (24.1%), and RUNX1 (10.6%). At diagnosis, 42.4% (268/632) of patients were TD. TD was associated with inferior survival irrespective of IPSS-M risk category (5-year OS: TD+IPSS-M HR: 39.1%, TD+IPSS-M LR: 49.4%, TI: 75.6%), and this adverse impact persisted in landmark analyses.

Among initially TI patients, the cumulative incidence of TD development reached 45.6%, with most conversions occurring within the first two years. IPSS-M higher-risk status (HR=2.413, 95% CI: 1.486-3.917, P<0.001) and MDS-LB (HR=2.202, 95% CI: 1.155-4.201, P=0.017) were associated with an increased risk of TD development.

In TD patients, allo-HSCT (n=66) conferred long-term survival benefit (HR=0.513, 95% CI:0.297-0.886, P=0.017), with a 5-year OS of 87.6% versus 48.9% in non-transplanted patients in the 12-month landmark analysis (P<0.001).

Among initially TI patients (n=364), a prognostic model incorporating RUNX1, U2AF1, del(7/7q), bone marrow blasts ≥2% and age>65 years provided additional risk discrimination beyond IPSS-M (C-index: 0.739 vs. 0.651). In TI patients harboring one of these adverse factors (excluding age), allo-HSCT was associated with improved survival in an 18-month landmark analysis (100.00% vs 73.71%, P=0.038).

Conclusions: TD represents a dynamic marker of adverse prognosis and identifies patients most likely to benefit from allo-HSCT. In initially TI patients, adverse biological features, including ≥2% bone marrow blasts, U2AF1 or RUNX1 mutations, and del(7/7q), may help identify candidates who could benefit from transplantation. These findings support a more individualized transplantation strategy integrating transfusion status and disease biology in MDS-h and MDS-LB.

Wenjing Guo, PhD: No relevant conflicts of interest to declare.